2024-10-19 - Analysis Report
## Amgen Inc (AMGN) Stock Analysis Report

**Company Overview:** Amgen Inc. is a leading biotechnology company that develops, manufactures, and markets innovative human therapeutics. 

**Performance Analysis:**

**1. Relative Performance:**

* **Cumulative return:** AMGN: 79.7%, VOO (S&P 500): 136.97%.
* **Performance Gap:** AMGN lags behind VOO by 57.27% (28.83% relative to historical performance range).

**2. Recent Price Movements:**

* **Closing price:** $321.33
* **5-day moving average:** $324.20
* **20-day moving average:** $323.24
* **60-day moving average:** $326.75

**3. Technical Indicators:**

* **RSI:** 41.21 (suggesting a slightly oversold condition)
* **PPO:** 0.08 (suggests weak momentum)
* **Delta_Previous_Relative_Divergence:** -12.14 (indicates a short-term downtrend)
* **Expected_Return:** 0.0% (suggests no significant expected return exceeding S&P 500 over the next 5 years).

**4. Recent Earnings and Outlook:**

| Date       | EPS  | Revenue      |
|------------|------|---------------|
| 2024-08-07 | 1.39 | $8.39 billion |
| 2024-05-03 | -0.21| $7.45 billion |
| 2023-10-31 | 3.23 | $6.90 billion |
| 2023-08-04 | 2.58 | $6.99 billion |

* **Most recent earnings:** The company exceeded earnings estimates of $1.33 per share with $1.39 EPS, showing a significant improvement from previous quarters. Revenue also surpassed expectations, indicating strong underlying business performance. 

**5. News and Recent Issues:**

* **Market Outlook:** The recent market outlook for Amgen is cautiously optimistic, with analysts citing the company's strong product portfolio, pipeline, and market position in the biotechnology sector. The stock is expected to benefit from growing demand for innovative therapeutics and the aging population globally.
* **Analyst Opinions:** Most analysts maintain a "Buy" or "Hold" rating on AMGN stock. 
* **Performance Highlights:** The company has shown impressive financial performance in recent quarters, with increased revenue and consistent growth.
* **FINBOLD Analysis:** FINBOLD notes that the company's stock is undervalued and has significant potential for growth. The company's recent earnings report reflects strong operational performance and a promising pipeline of new drugs.


**6. Overall Analysis:**

Amgen Inc. shows a mixed picture. While the company demonstrates strong fundamentals with recent earnings exceeding expectations and a promising pipeline, its stock performance lags behind the S&P 500. The technical indicators suggest a short-term downtrend and weak momentum, but the overall market outlook remains cautiously optimistic.

**7. Investment Recommendation:**

Given the mixed picture, investors should carefully consider the potential risks and rewards of investing in AMGN. The company's strong fundamentals suggest long-term growth potential, but its current performance and market volatility require further evaluation. A long-term perspective and a thorough understanding of the company's business and industry are essential for making an informed investment decision. 
